Also, AB SCIEX is working closely with clinical research laboratories throughout the world to develop applications for fast, sensitive and robust technology. We aim to offer complete solutions for research laboratories combining industry-leading systems, software and pre-configured methods with comprehensive service and support.

Another area where AB SCIEX has been getting strong support from its customers is biomarkers. Biomarkers hold the potential to improve human condition. By providing the basis for earlier and more accurate diagnostic tests, they may help clinicians to detect and treat diseases. And as surrogate end-points they allow pharmaceutical companies to make better and more targeted drugs to treat diseases.

What are the factors that distinguish AB SCIEX from its competitors? What are your strategies?

Mr Ho: What distinguishes us are our integration strategies - integrating quantitative and qualitative analysis as well as developing integrated workflows that provide complete solutions and service for our customers. Our service and support are also best-in-class, giving mass spectrometry users greater confidence than what they will get elsewhere.

Asia is very sensitive towards pricing. What are your pricing strategies for innovative technology?